Results 161 to 170 of about 18,687 (213)
Some of the next articles are maybe not open access.
The fate of ritonavir in the presence of darunavir
International Journal of Pharmaceutics, 2014This study was the first investigation into the potential of a fixed dose combination of ritonavir and darunavir in the form of dispersible powders prepared by spray drying. A common polymer (hydroxypropyl methylcellulose, polyvinylpyrrolidone, and polyvinylpyrrolidone-vinyl acetate 64) was formulated with either ritonavir or darunavir or a combination
D N, Nguyen, G, Van den Mooter
exaly +3 more sources
Drugs of Today, 2007
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire +4 more sources
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire +4 more sources
Pharmacoeconomics of darunavir
Expert Review of Pharmacoeconomics & Outcomes Research, 2011Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008.
Dwight S, Fullerton +3 more
openaire +2 more sources
Darunavir: A comprehensive profile
2021Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV).
Ibrahim A, Darwish +5 more
openaire +2 more sources
Clinical Pharmacokinetics of Darunavir
Clinical Pharmacokinetics, 2007Darunavir (TMC114) is a newly developed HIV-1 protease inhibitor with potent antiviral activity against both wild-type and multidrug resistant HIV-1 strains. The drug is currently approved by the US FDA for antiretroviral treatment-experienced patients with limited therapeutic options.
Michael, Rittweger, Keikawus, Arastéh
openaire +2 more sources
Enfermedades Infecciosas y Microbiología Clínica, 2008
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +2 more sources
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +2 more sources
Darunavir for the treatment of HIV infection
Expert Opinion on Pharmacotherapy, 2018Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both naïve and experienced subjects due to its high genetic barrier and efficacy. The introduction in clinical practice of integrase strand transfer inhibitors limited its role in the management of naïve subjects and in antiretroviral
Vincenzo Spagnuolo +2 more
openaire +2 more sources